Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on Monday, March 13, 2023
Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, announced a conference call scheduled for March 13, 2023, at 4:30 p.m. ET. The call aims to report its fourth quarter and full-year financial results while providing updates on its business and pipeline. Spero focuses on developing treatments for rare diseases and multi-drug resistant bacterial infections. Key candidates include SPR720 for non-tuberculous mycobacterial infections, Tebipenem HBr for complicated urinary tract infections, and SPR206, targeting multi-drug resistant Gram-negative infections.
- Upcoming conference call to discuss fourth-quarter and full-year financial results, indicating transparency and communication with investors.
- Development of SPR720, a novel oral therapy for a rare pulmonary disease, highlighting innovative treatment options.
- Tebipenem HBr and SPR206 in pipeline, addressing significant unmet medical needs in bacterial infections.
- Tebipenem HBr is still investigational and not FDA-approved, posing a risk for potential market entry delays.
- The company is in a clinical-stage, which typically involves high uncertainty and risks in drug development.
CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas, involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, March 13, 2023 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an update on its business and pipeline.
To access the call, please dial 1-877-704-4453 (domestic) or 1-201-389-0920 (international) and refer to conference ID 13736217, or click on this link and request a return call. The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days following the call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including rare diseases and multi-drug resistant bacterial infections.
- Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
- Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.
For more information, visit https://sperotherapeutics.com.
Investor Relations Contact:
Ted Jenkins
Vice President, Investor Relations and Strategic Finance
IR@sperotherapeutics.com
(617) 798-4039
Media Inquiries: Lora Grassilli, Health Media Relations
Zeno Group
lora.grassilli@zenogroup.com
646-932-3735
FAQ
When is Spero Therapeutics' next conference call?
What financial results will Spero Therapeutics report?
What is the status of Tebipenem HBr?
What diseases is Spero Therapeutics developing treatments for?
What pipeline candidates is Spero Therapeutics working on?
